Immunomedics, Inc. (IMMU) - NASDAQ
  • Wed, May 4, 4:01 PM
    • Immunomedics (NASDAQ:IMMU): FQ3 EPS of -$0.15 misses by $0.02.
    • Revenue of $0.9M (-23.7% Y/Y) misses by $1.23M.
    • Press Release
    | Wed, May 4, 4:01 PM
  • Wed, May 4, 4:01 PM
    • Immunomedics (NASDAQ:IMMU): FQ3 EPS of -$0.15 misses by $0.02.
    • Revenue of $0.9M (-23.7% Y/Y) misses by $1.23M.
    • Press Release
    | Wed, May 4, 4:01 PM
  • Thu, Feb. 4, 11:05 AM
    • Immunomedics (IMMU +11.9%) FQ2 results: Revenues: $0.6M (-25.0%); R&D Expense: $0.06M (-70.0%); Operating Loss: ($15.7M) (-36.5%); Net Loss: ($13.7M) (-20.2%); Loss Per Share: ($0.15) (-25.0%); Quick Assets: $76M (-23.7%).
    • No guidance given.
    | Thu, Feb. 4, 11:05 AM
  • Wed, Feb. 3, 4:02 PM
    • Immunomedics (NASDAQ:IMMU): FQ2 EPS of -$0.15 misses by $0.01.
    • Revenue of $0.7M (-30.0% Y/Y) misses by $0.53M.
    | Wed, Feb. 3, 4:02 PM
  • Nov. 4, 2015, 4:16 PM
    • Immunomedics (NASDAQ:IMMU): FQ1 EPS of -$0.16 misses by $0.02.
    • Revenue of $0.73M (-31.8% Y/Y) misses by $0.5M.
    | Nov. 4, 2015, 4:16 PM
  • Aug. 20, 2015, 7:18 AM
    • Immunomedics (IMMU -4.7%) FQ4 results: Revenues: $2.4M (+100.0%); Operating Expenses: $13.6M (+3.8%); Operating Loss: ($11.2M) (+5.9%); Net Loss: ($12.4M) (-5.1%); Loss Per Share: ($0.13) (unch).
    • FY2015 results: Revenues: $5.7M (-36.7%); Operating Expenses: $51.9M (+16.4%); Operating Loss: ($46.2M) (-29.8%); Net Loss: ($48M) (-35.6%); Loss Per Share: ($0.51) (-21.4%); Quick Assets: $99.6M (+138.3%).
    • No guidance given.
    | Aug. 20, 2015, 7:18 AM
  • Aug. 19, 2015, 4:02 PM
    • Immunomedics (NASDAQ:IMMU): FQ4 EPS of -$0.13 in-line.
    • Revenue of $2.4M (+101.7% Y/Y) beats by $1.27M.
    | Aug. 19, 2015, 4:02 PM
  • May 6, 2015, 4:05 PM
    • Immunomedics (NASDAQ:IMMU): FQ3 EPS of -$0.13 in-line.
    • Revenue of $1.2M (+4.3% Y/Y) beats by $0.13M.
    | May 6, 2015, 4:05 PM
  • Feb. 4, 2015, 4:47 PM
    • Immunomedics (NASDAQ:IMMU): FQ2 EPS of -$0.12 beats by $0.01.
    • Revenue of $1M (-16.7% Y/Y) misses by $0.38M.
    | Feb. 4, 2015, 4:47 PM
  • Nov. 5, 2014, 5:47 PM
    • Immunomedics (NASDAQ:IMMU): FQ1 EPS of -$0.13 misses by $0.01.
    • Revenue of $1.1M (-80.0% Y/Y) misses by $0.04M.
    | Nov. 5, 2014, 5:47 PM
  • Oct. 27, 2014, 12:09 PM
    • Immunomedics (IMMU) will report fiscal Q1 results on November 6 in the morning. The conference call will begin at 10:00 am ET.
    • Consensus view is a loss of ($0.12) on revenues of $1.1M
    | Oct. 27, 2014, 12:09 PM
  • Aug. 25, 2014, 4:17 PM
    • Immunomedics (IMMU +3.5%) fiscal Q4 and full year results:
    • Fiscal Q4: Revenues: $1.2M (-12.8%); Operating Expenses: $13.1M (+44.7%); Net Loss: ($11.9M) (-53.3%); Loss Per Share: ($0.13) (-44.4%); Quick Assets: $41.8M (+1.2%).
    • Fiscal 2014: Revenues: $9.0M (+80.0%); Operating Expenses: $44.6M (+24.6%); Net Loss: ($35.4M) (-210.5%); Loss Per Share: ($0.42) (-180.0%).
    • No financial guidance given.
    | Aug. 25, 2014, 4:17 PM
  • Aug. 25, 2014, 4:02 PM
    • Immunomedics (NASDAQ:IMMU): FQ4 EPS of -$0.13 misses by $0.01.
    • Revenue of $1.2M (-11.8% Y/Y) in-line.
    | Aug. 25, 2014, 4:02 PM
  • May 7, 2014, 5:06 PM
    • Immunomedics (IMMU -3.1%) total revenues: $1.2M (-29.4%); product sales: $925.2K (+23.1%); operating loss: ($9.5M) (-15.9%); net loss: ($9.5M) vs $8.6M; loss/share: ($0.11) vs $0.11; quick assets (ex-A/R): $20.9M (-49.4%).
    | May 7, 2014, 5:06 PM | 1 Comment
  • Feb. 10, 2014, 4:28 PM
    • Immunomedics, Inc. (IMMU): FQ2 EPS of $-0.10 in-line.
    • Revenue of $1.2M (+50.0% Y/Y)
    | Feb. 10, 2014, 4:28 PM | 2 Comments
Company Description
Immunomedics, Inc. is a biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer,... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States